The Clinical Trials Grant from the Osteosarcoma Institute supports researchers planning to conduct clinical trials in osteosarcoma. The proposed trial may be conducted at a single institution, a clinical trial consortium, or through an existing clinical trial infrastructure. The primary objective of proposed Phase I/II or Phase II clinical trials should be to improve event-free survival (EFS) at 4 months, beyond historical rates known to be in the range of 12%. The proposed trial may be carried out in a single institution, a clinical trial consortium, or through an existing clinical trial infrastructure. OSI will not prioritize the launch of new infrastructures to conduct clinical trials

Eligibility

• Funds must be granted to nonprofit/charitable institutions or organizations.
• Applicants need not be United States citizens.
• Applicants must have an MD, PhD, MD/PhD, or equivalent and be appointed as faculty (or equivalent) at an academic institution.  Applicants must have a track record of publication and funding productivity that demonstrates the project can be accomplished by the investigators.
• Applicants selected for funding will permit OSI to publicize the grant for fundraising purposes, including, but not limited to a five-minute video discussing the research project, photos of the lab, and photos of children participating in clinical trials, where applicable.
• Applications that do not follow the specific grant application instructions and/or submission process will not be considered.

Applicants may apply for up to 800,000 USD, including up to 10% indirect costs for 2 years.

Letters of intent are due on October 24,